Replies to post #235715 on Avid Bioservices Inc (CDMO)

[md1225]

NYC two days ago Austria next weekend Then strategic summit with our Gilead club house pal!

[biopharm]

Experience

Sr. Director Medical Affairs
Peregrine Pharmaceuticals, Inc.
March 2015 – Present (7 months)Tustin, CA

Director Clinical Research-Oncology and Inflammation Therapeutics
Gilead Sciences
July 2012 – Present (3 years 3 months)Foster City, CA

Senior Director, Medical Affairs
Allos Therapeutics
June 2010 – July 2012 (2 years 2 months)

Senior Regional Manager, BioOncology, MSLs
Genentech
August 2003 – June 2010 (6 years 11 months)

.....

March 12, 2009, Roche announced a $46.8 billion deal to buy South San Francisco, Calif.-based Genentech.

Sept 1st 2010
Once pharmaceutical giant Roche Holding decided to acquire full ownership of biotech firm Genentech, leadership at Roche knew there was no going back. Although the two companies had been working together in some form since the 1980s, and Roche had owned a controlling stake in Genentech since 1990, executives at the Swiss pharma company realized that a failed takeover would permanently poison any future dealings between the two. “If we had gone down the path of increasing the ownership stake … it would have been different,” Steve Krognes, a former Roche executive who is now senior vice president and CFO of Genentech, said during a recent presentation at Wharton San Francisco. “But once the decision was made that we were going to go for full acquisition, and that was announced publicly, there was no way back.”

http://knowledge.wharton.upenn.edu/article/anatomy-of-a-merger-hostile-deals-become-friendly-in-the-end-right/

-----------------

So one big move was from Genentech to Allos and this move makes sense as there were layoffs coming... just follow the timeline above and layoffs looming below...

Nov 17, 2010

Genentech, the South San Francisco-based biotech giant, announced its layoff plan this morning, and hundreds of Bay Area jobs will be trimmed from the company's 10,000-employee payroll in California.

Genentech was acquired for $47 billion by Switzerland's Roche Holding AG last year, and the layoffs were rumored to be coming earlier this week as part of Roche's corporate cost cutting.

https://www.baycitizen.org/news/business/genentech-layoff-hundreds-bay-area/

------------------

July 2012

Spectrum Pharmaceuticals Completes Acquisition of Allos Therapeutics; Effective and Swift Integration Expected to Result In Significant Synergies

http://www.businesswire.com/news/home/20120906005797/en/Spectrum-Pharmaceuticals-Completes-Acquisition-Allos-Therapeutics-Effective#.Vf8fOJf76So

-------------------

So we covered her move from Genentech to Allos and now we all know synergies = layoffs so this timeline makes sense as she starts Gilead exactly in July 2012.... as she moved from Sr. Reg. Manager, Sr. Director and competitively settled for "Director.." at Gilead.....

So I'm just pointing out that she doesn't really move on, unless an opportunity exists....hey,could be due to projected layoffs if they make a bigger acquisition.

Finally, I just think someone with her experience and knowledge, especially in projecting where the industry is headed into the IO space, all just does not make sense that she goes somewhere that will not be part of the IO space in a big way.... and of course the profile of showing both companies or are they already one?

[biopharm]

Lisa Stepp, Senior Director Medical Affairs for PPHM is listed as Faculty of the upcoming Medical Affairs Strategic Summit in San Diego 9/30-10/2.

ECG, after a couple days of this to sink in and after seeing Lisa and her association with only Peregrine in this upcoming Summit in San Diego "only" showing Peregrine and not Gilead has me curious and I'd say she will do better than Vladimir Evilevitch

------------

STRATEGIES FOR MSL OPERATIONAL IMPROVEMENT AND TEAM
RETENTION
• Hear best practices to manage a team of MSLs and effectively
communicate goals, compliance expectations and limitations
• Explore different corporate initiatives to motivate and achieve higher retention of MSLs
• Learn about the most common mistakes made when managing field
teams and how to improve communication with MSLs

Lisa Stepp, Senior Director Medical Affairs,
PEREGRINE PHARMACEUTICALS, INC.

http://info.exlevents.com/rs/195-NER-971/images/C593-MassWestBrochure.pdf

-------------------------------

Sr. Director Medical Affairs
Peregrine Pharmaceuticals, Inc.
March 2015 – Present (7 months)Tustin, CA

Director Clinical Research-Oncology and Inflammation Therapeutics
Gilead Sciences
July 2012 – Present (3 years 3 months)Foster City, CA

https://www.linkedin.com/pub/lisa-stepp-phd-mba/a/942/345

-----------------------------

[biopharm]

More events lined up for Lisa Stepp

http://exlevents.com/medical-affairs-executive-forum-west/faculty/